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to success after reduced intensity conditioning (RIC) alloge-
neic hematopoietic stem cell transplantation (HSCT) for pa-
tients with acute leukemia and MDS. The ideal RIC regimen
has not been deﬁned. Clofarabine is a nucleoside analogue
with potent anti-leukemia activity and its inclusion in RIC
HSCT could potentially lead to decreased rates of disease
relapse.
Methods: We conducted a phase II clinical trial of reduced
intensity busulfan (6.4 mg/kg IV total) with clofarabine (40
mg/m2 IV daily x 4 days) conditioning before allogeneic 8/8
HLA-matched related or unrelated donor HSCT. GVHD pro-
phylaxis was with tacrolimus and methotrexate (5 mg/m2 on
days 1, 3, 6). The primary endpoint was donor neutrophil
engraftment by day +40 after HSCT. Secondary endpoints
included non-relapse mortality, rates of acute and chronic
GVHD, PFS, and OS.
Results: 34 patients with AML (n¼24), MDS (n¼6), and ALL
(n¼4) were enrolled and underwent RIC HSCT. Patients with
AML or ALL were in CR and patients with MDS had < 10%
bone marrow blasts. The median age of patients was 63.5
(range 25, 74) and median HCT-CI score was 1 (range 0, 9).
Engraftment with donor chimerism by day +40 was achieved
in 33 of 34 patients with one patient dying before successful
count recovery. Of the patients who engrafted and had
chimerism data available (n¼30), median donor chimerism
measured at approximately day +30 after HSCT was 97%
(range 85%, 100%) for all leukocytes and median 80% (50%,
100%) for the CD3+ population. Of those who have been fol-
lowed for at least 100 days after HSCT (n¼28), the probability
of NRM at day 100 was 6.4% and 1-year was 36% (95% CI, 15%,
57%). Causes of NRM included acute GVHD (n¼4), infection
(n¼2), and multi-organ failure (n¼2). Four of the six patients
with MDS died of NRM, all of whomwere older than 65 and
had HCT-CI scores 4 or above. The other two non-relapse
deaths were due to acute GVHD in the setting of early taper
of tacrolimus, one for decreasing chimerism and the other for
neurological complications. There were no cases of hepatic
VOD. The 12-month cumulative incidence of disease relapse
was 27% (95% CI, 12%, 44%). The 6-month cumulative inci-
dence of acute GVHD was 35% (95% CI, 18%, 53%) and the 12-
month cumulative incidence of chronic GVHD was 24% (95%
CI, 9.2%, 43%). The 12-month probability of PFS was 38% (95%
CI, 18%, 59%) and OS was 41% (95% CI, 19%, 62%).
Conclusion: Reduced intensity conditioning with busulfan
and clofarabine engenders successful donor engraftment
with acceptable rates of toxicity, NRM, and GVHD, although
caution should be used in older patients with signiﬁcant
comorbidities. Longer follow-up and comparison of out-
comes with ﬂudarabine-based regimens will be important in
deﬁning the role of this RIC regimen.335
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Introduction: Fungi are among the most common microbes
encountered by mammalian hosts and a major cause of
morbidity and mortality of allogeneic hematopoietic stem
cell transplantation (HSCT). Both innate and adaptive im-
munity prevent invasive fungal infections (IFI), and are
impaired after HSCT. Due to Candida prophylaxis, Aspergillus
and other molds are emerging as one of the main causes ofnon-relapse mortality (NRM) after allogeneic HSCT. In this
study, we retrospectively evaluated the incidence of IFI and
their impact on the outcomes of allogeneic HSCT.
Methods: The data was obtained from University of Michi-
gan Blood and Marrow Transplant Program database under
an IRB-approved protocol. We included only proven and
probable fungal infections, deﬁned according EORTC/MSG
criteria (CID 2008; June 15;46 (12):1813).
Results: A total of 50 IFI were diagnosed in 542 patients
between 2007 and 2012, 76% (n¼37) due to mold mostly
represented by Aspergillus (n¼24, 63%), followed by Zygo-
myces and Rhizopus. Only 3/37 infections were diagnosed in
2012, probably reﬂecting more consistent prophylaxis
against mold during this period. The CI of mold infections
was 6.6% (95% CI 5-10%) and 10.4% (95% CI 8-14%) at 1 and 2
years respectively, with a median time to infection of 194
days (9-644). The median prednisone dose was 15 mg at the
time of diagnosis, with a median duration of therapy of 124
days (0-1757). Mold infections were signiﬁcantly more
common in patients with a history of acute GVHD (aGVHD, CI
at 1y 10.3% vs. 0.2%, HR¼6.2, p¼0.0001), but not in those
with chronic GVHD (cGVHD, CI at 1y 5.4 vs. 7.7%, HR¼0.7,
p¼0.2). The case fatality rate of mold infections was high at
83.3%, and they were associated with a substantial increase
in NRM both in aGVHD (70 vs. 34% at 2 ys, HR¼2.6, 1.68-4.1)
and cGVHD (43% vs. 15% at 2y, HR¼4, 2.2-7.5). After adjusting
for other HSCT-related factors, mold infections persisted as
an independent risk factor for NRM for patients with both
aGVHD (HR¼2.78, 1.7-4.4) and cGVHD (HR¼4, 2-7).
Conclusions: Mold infections are emerging as a major cause
of infection-related mortality, with a very high case fatality
rate and a signiﬁcant impact on NRM in patients with aGVHD
and cGVHD. Our data further supports the need for anti-mold
prophylaxis in high-risk populations.336
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Human Herpesvirus Type 6 (HHV-6) reactivation occurs in
38%-67% of hematopoietic stem cell transplant (HSCT) re-
cipients eusually within the ﬁrst month post-transplant.
Studies have shown that HHV-6 reactivation after allogeneic
HSCT delays engraftment, has myelosuppressive effects, and
potentially increases the risk of developing acute graft-
versus-host disease (aGVHD). An increased incidence of
HHV-6 reactivation in umbilical cord blood (UCB) HSCTs has
been previously described.
In June 2012, Weill Cornell Medical Center began performing
allogeneic HSCTs with haploidentical stem cells followed by
UCB (Haplo-Cord). No published studies have examined
HHV-6 reactivation and its sequelae in Haplo-Cord HSCTs.
The purpose of this study was to retrospectively assess for
risk factors and sequelae of HHV-6 reactivation in UCBHSCTs.
The objectives were to determine the impact of early HHV-6
reactivation (within 60 days of transplant) on overall survival
and incidence of aGVHD at 100 days post-transplantation.
Fifty-seven adult transplants between August 2010 and June
2013 utilizing UCB with  1 HHV-6 PCR level reported were
included: 29 double UCB HSCTs, 26 Haplo-Cord HSCTs, and 2
single UCB HSCTs.
HHV-6 reactivation occurred in 35/57 (61.4%). No baseline
factors (age, ASBMT RFI disease classiﬁcation, conditioning
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time to engraftment, and underlying disease) predicted for
HHV-6 reactivation.
Comparing HSCTs with HHV-6 reactivation and those
without, survival at 100 days (77% v. 73%, p¼0.706) and
development of aGVHD (57% v. 32%, p¼0.062) were not
signiﬁcantly different. HHV-6 reactivation with > 1000
copies/mL trended towards increased development of
aGVHD (63% v. 36%, p¼0.051). Notably, aGVHD developed
signiﬁcantly less often in Haplo-Cord HSCTs compared to
HSCTs only using UCB (31% v. 61%, p¼0.022).
Based on preliminary analysis, early HHV-6 reactivation after
UCB HSCT occurs indiscriminately and does not inﬂuence
survival or incidence of aGVHD at 100 days post-trans-
plantation.Figure 1.337
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Background: HHV-6 infection, mainly encephalitis, may
cause signiﬁcant morbidity and mortality among HSCT re-
cipients. Despite the interest in HHV-6 in immunocompro-
mised patients, however, little is known about the clinical
signiﬁcance of HHV-6 DNAemia in HSCT recipients.
Methods: We reviewed the medical records of all HSCT re-
cipients with positive HHV-6 DNA in serum (n¼68) deter-
mined by real-time PCR assays between Nov 2008 and Apr
2012. We sought to determine the demographics, clinical
characteristics, and outcome of HHV-6 DNAemia in this pa-
tient population.
Results: Majority were white (43, 63%) males (35, 51%) with
a median age of 54 y (range: 2- 74 y) who had undergone
matched related (15, 22%), unrelated (19, 28%), and cord
blood (18, 26%) transplants. Melphalan-based therapy (34,
50%) was the most common conditioning regimen. Cortico-
steroids (41, 61%), tacrolimus (52,76%), and mycophenolate
(24, 35%) were commonly used. Acute GvHD was identiﬁed
in 38 pts (56%). All pts were on prophylactic dose of valacy-
clovir or acyclovir prior to the ﬁrst positive HHV-6 DNAemia
and the geometric mean titer (GMT) was 16,336 copies/mL
(range: 540 - 5431497 copies/mL) within amedian time from
HSCT of 29 d (range: 13-390 d). Main reasons for HHV-6
testing included persistent fever (40%), mental status
changes (26%), and delayed engraftment (9%). Regardless of
antiviral therapy which was administered in 62% of the pts
(foscarnet; 88%), most patients (68%) recovered with nega-
tive DNAemia, had symptom resolution (53%), or progressed
to meningoencephalitis (14%). HHV-6 related mortality
occurred in 3 pts (5%) despite antiviral therapy (2 encepha-
litis and 1 pneumonitis).
Conclusions: Despite receiving antiviral therapy, HHV-6
DNAemia progressed to end-organ disease with serious
complications in some HSCT recipients but most pts recov-
ered with or without therapy. Whether timely preemptivetherapy prevented HHV-6 end-organ disease still needs to be
determined in randomized trials.338
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Background: Allogeneic hematopoietic cell transplantation
(HCT) likely prolongs survival in high and intermediate risk
adults with acute myeloid leukemia (AML). Prior studies,
however, suggest that only about 15-20% of AML patients
especially older than 50 with abnormal cytogenetics receive
HCT. In this report, we evaluated the impact of transplant and
preparative regimen on high- or intermediate-risk AML pa-
tients treated in our center.
Methods: We retrospectively reviewed all patients who
were diagnosed with AML (non promyelocytic) in our center
between 2002 and 2012. Primary objective was to study the
impact of HCT and preparative regimen in high and inter-
mediate risk AML patients. Demographics and disease-
related variables were collected. OS was deﬁned as the time
from diagnosis to the time of death or last follow up.
Results: Between 2002 and 2012, 123 patients with high or
intermediate risk AML patients were treated at our center.
Median age at diagnosis was 60 (range 19-89). 82 patients
had high-risk features while 41 had intermediate risk fea-
tures. Median OS for all patients was 368 days.
Of these 124 patients, ﬁfty-one patients (41%) received
allogeneic HSCT at a median of 4.6 months from diagnosis.
Median age of patients who received HCT was 53 while
median age of patients who did not get HCTwas 68. Of the 51
patients who received HCT,13 patients withmedian age of 61
received a reduced toxicity/ Intensity conditioning regimen
(RIC) while 37 patients withmedian age of 49 received a fully
myelo-ablative regimen (MA). One got transplant elsewhere
with unknown regimen. Median percentage of blasts in bone
marrow at time of HCT was 3 and 3.5% for the RIC and MA
regimens, respectively. Number of patients who had 10% or
more blasts in the bone marrow at transplant was 9 of the 37
